Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — April 2024

Genmab — April 2024

Planlagt Fastgjort Låst Flyttet Genmab
759 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • V Offline
    V Offline
    Vitus
    wrote on sidst redigeret af
    #719

    Betyder det noget…..

    1 Reply Last reply
    0
    • W Offline
      W Offline
      w
      wrote on sidst redigeret af
      #720

      Alt er indregnet;)

      1 Reply Last reply
      0
      • V Offline
        V Offline
        Vitus
        wrote on sidst redigeret af
        #721

        Vor herre bev……

        1 Reply Last reply
        0
        • royalR Offline
          royalR Offline
          royal
          wrote on sidst redigeret af
          #722

          Lige før man håber på et dårligt Q1 på torsdag.

          1 Reply Last reply
          0
          • W Offline
            W Offline
            w
            wrote on sidst redigeret af
            #723

            Komplet uforståeligt at den kan falde på en godkendelse, der iøvrigt kom før tid

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #724

              This full approval is the minimum requirement to continue with Tivdak and therefore an important step. It will depend on how much new owner Pfizer sees in the drug, but the EMA application and current conversations with regulators to continue also in head and neck cancer bode well for now.

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #725

                Tivdak seems to go a little bit under the radar, but 'According to GlobalData’s patient-based forecast, Tivdak is forecast to generate sales of $1.4bn in the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada) by 2030'

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #726

                  Link Preview Image
                  Highlights from ESMO 2023: Antibody-drug conjugates and bispecific T-cell engagers

                  At ESMO 2023, much of the focus was on new data for antibody-drug conjugates (ADCs) and bispecific T-cell engagers (BiTEs)

                  favicon

                  Clinical Trials Arena (www.clinicaltrialsarena.com)

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #727

                    i am sure we will still all be here in 2030 to see if that comes true, whilst complaining about the share price 😉

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      Bullish
                      wrote on sidst redigeret af
                      #728

                      OB og Genmab har noget til fælles for tiden..

                      1 Reply Last reply
                      0
                      • R Offline
                        R Offline
                        Riis7
                        wrote on sidst redigeret af
                        #729

                        Og fcm:-)

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          GeorgeBest
                          wrote on sidst redigeret af
                          #730

                          Thanks E L 09:48. Can you also see what’s the forecast for epcoritamab is by 2030?

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #731

                            'GlobalData’s consensus forecast forecasts that Epkinly will achieve blockbuster status by 2027, with global sales expected to exceed $1.9bn by 2029.' from may last year https://www.clinicaltrialsarena.com/analyst-comment/abbvie-genmab-epkinly-dlbcl/?cf-view

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #732

                              Due to Epkinly's tremendous efficacy, analysts at SVB Securities think that the drug could reach peak annual sales of $3 billion in the U.S. https://www.nasdaq.com/articles/could-this-new-drug-be-a-blockbuster-for-these-2-pharma-collaborators

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #733

                                Sydbank epcoritamab
                                He estimates the new drug’s annual peak sales potential at USD 3.5bn.https://medwatch.com/News/Pharma___Biotech/article15855008.ece

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #734

                                  Drug: Epcoritamab
                                  Companies: AbbVie and Genmab
                                  Used for: Lymphoma
                                  Est. 2028 sales: $1.7 billion https://www.fiercepharma.com/marketing/top-10-most-anticipated-drug-launches-2023

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #735

                                    Jefferies analysts previously predicted Epkinly could reach about $2.75 billion in peak sales.

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #736

                                      Take your pick 😉

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #737

                                        the strength of the competition will greatly affect epco sales, it will be a battle

                                        1 Reply Last reply
                                        0
                                        • L Offline
                                          L Offline
                                          lahn1
                                          wrote on sidst redigeret af
                                          #738

                                          wise guy 😉

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper